OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open‐Label ( COMPEL ) trial
Headache: The Journal of Head and Face Pain · 2026
DOI: 10.1111/head.70007 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2026. Verfasst von Andrew M Blumenfeld und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Los Angeles Headache Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Botulinum Toxins, Type A, Neuromuscular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Objective
Examine treatment responses to and safety of onabotulinumtoxinA for the preventive treatment of chronic migraine ( CM ) among diverse racial groups.
Background
Evidence suggests there are differences in headache treatment patterns, symptom profiles, and burden based on race. However, limited data are available describing the response to preventive migraine treatments among these groups.
Methods
The C hronic Migraine O nabotulinu M toxinA P rolonged E fficacy open L abel ( COMPEL ) trial was a single‐arm, open‐label, multicenter, prospective study (January 23, 2012–November 16, 2015) that enrolled adults of various races with CM to receive onabotulinumtoxinA 155 U every 12 weeks over 108 weeks. These analyses assessed White, Asian (primarily Republic of Korea residents), and Black/African American subgroups based on self‐report. Pacific Islander/American Indian/Alaska Native and Hispanic/Latinx subgroups were not analyzed separately because of the small sample sizes and potential overlap with predefined racial categories (e.g., Hispanic/Latinx White) for the latter. Analyses of baseline demographics and clinical characteristics, including headache features, across the subgroups were performed. Change from baseline in the number of monthly headache days ( MHDs ), including proportions with ≥50% reduction in MHDs , and change from baseline scores on the 6‐item Headache Impact Test ( HIT ‐6), Migraine Disability Assessment ( MIDAS ) absenteeism, presenteeism, and total scores, and Migraine‐Specific Quality of Life questionnaire version 2.1 ( MSQ v2.1) Role Function–Restrictive ( RFR ), Emotional Function ( EF ), and Role Function–Preventive ( RFP ) domains were evaluated for each subgroup.
Results
Of 716 enrolled participants, 582 (81.3%) were White, 89 (12.4%) were Asian, 41 (5.7%) were Black/African American, and 4 (0.6%) were Pacific Islander/American Indian/Alaska Native. Withdrawal from the study occurred for 50.5% of the White subgroup, 32.6% of the Asian subgroup, and 48.8% of the Black/African American subgroup. The most common reasons for study discontinuation were participant withdrawal of granted consent (12.8%) and lost to follow‐up (11.5%). After treatment with onabotulinumtoxinA 155 U every 12 weeks, all subgroups demonstrated significant reductions from baseline in MHDs at all time points to week 108 (all p < 0.001) and 60.3%–73.3% experienced ≥50% reduction from baseline in MHDs at week 108. Each analyzed subgroup demonstrated significant reductions from baseline to week 108 in HIT ‐6 total (all p < 0.001), MIDAS total (White, p < 0.001; Asian, p < 0.001; Black/African American, p = 0.0062), MIDAS absenteeism (White, p < 0.001; Asian, p < 0.001; Black/African American, p = 0.002), MIDAS presenteeism (all p < 0.001), MSQ v2.1 RFR (all p < 0.001), MSQ v2.1 EF (White, p < 0.001; Asian, p < 0.001; Black/African American, p = 0.009), and MSQ v2.1 RFP (all p < 0.001) scores. Results in the total population were similar to those in the subgroups. Treatment‐related adverse events were consistent with the known safety profile of onabotulinumtoxinA .
Conclusions
OnabotulinumtoxinA safely reduced MHD frequency and patient‐reported disability and improved quality of life as a preventive treatment of CM among diverse subgroups, with results directionally consistent among groups. Trial Registration COMPEL, ClinicalTrials.gov identifier: NCT01516892.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Los Angeles Headache Center, Los Angeles, California, USA.
- Department of Neurology and Ophthalmology, Charleston Health Neurology & Head Pain Consultants, Pinckney, Michigan, USA.
- Westport Headache Institute, Westport, Connecticut, USA.
- Rehabilitation & Neurological Services, Huntsville, Alabama, USA.
- The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
- AbbVie, North Chicago, Illinois, USA.
ORCID-Profile: Larry Charleston, Hope L O'Brien
Förderung
- AbbVie
Zitieren
APA
Blumenfeld, A. M., Charleston, L., Kuruvilla, D., Savage-Edwards, B., Lipton, R. B., Singh, R., Jacob, P., Lawrence, N. A., Wang, C., & O'Brien, H. L. (2026). OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open‐Label ( COMPEL ) trial. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70007
Vancouver
Blumenfeld AM, Charleston L, Kuruvilla D, Savage-Edwards B, Lipton RB, Singh R, et al. OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open‐Label ( COMPEL ) trial. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70007
BibTeX
@article{Blumenfeld2026,
author = {Blumenfeld, Andrew M and Charleston, Larry and Kuruvilla, Deena and Savage-Edwards, Belinda and Lipton, Richard B and Singh, Ritu and Jacob, Patricia and Lawrence, Nicole A and Wang, Cuiwei and O'Brien, Hope L},
title = {OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open‐Label ( COMPEL ) trial},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
doi = {10.1111/head.70007}
}
EUVIMED